Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Kausik K. Ray, Helen M. Colhoun, Michael Szarek, Marie Baccara-Dinet, Deepak L. Bhatt, Vera A. Bittner, Andrzej Budaj, Rafael Diaz, Shaun G. Goodman, Corinne Hanotin, Robert A. Harrington, J. Wouter Jukema, Virginie Loizeau, Renato D. Lopes, Angèle Moryusef, Jan Murin, Robert Pordy, Arsen D. Ristic, Matthew T. Roe, José TuñónHarvey D. White, Andreas M. Zeiher, Gregory G. Schwartz, Philippe Gabriel Steg, ODYSSEY OUTCOMES Committees and Investigators, Philip E. Aylward, Sang-Hyun Kim, Robert Vogel, Philip Roberts-Thomson, Sam J. Lehman, Simon Robinson, Richard Davies, Jingfeng Wang, Yi Feng, David Alan, Peter Kaiser Nielsen, Simon Smith, David Henderson

Research output: Contribution to journalArticlepeer-review

139 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial'. Together they form a unique fingerprint.

Medicine & Life Sciences